Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Maximum Age: 65
Healthy Volunteers: f
View:
• Age between 45 and 65 years old
• Both sexes
• Patients with Parkinson's disease on dopamine replacement therapy
• Modified Hoehn and Yahr stage, MHY 1-4 (29)
Locations
Other Locations
Egypt
Tanta Hospital for Mental Health
RECRUITING
Tanta
Contact Information
Primary
Nour Elsherbeny, MSc
nelsherbeny@horus.edu.eg
01286911189
Time Frame
Start Date: 2025-05-10
Estimated Completion Date: 2026-05-30
Participants
Target number of participants: 50
Treatments
Active_comparator: Control group
25 patients who will receive their standard dopamine replacement therapy for 6 months
Active_comparator: Silymarin group
25 patients who will receive their standard dopamine replacement therapy plus silymarin 140mg three times daily for 6 months
Related Therapeutic Areas
Sponsors
Leads: Tanta University
Collaborators: Dr. Raed Ahmed Abdel-Maboud,Lecturer of neurology,Faculty of Medicine,Tanta University, Prof. Sahar Kamal Hegazy,Head of Clinical Pharmacy Department,Faculty of Pharmacy,Tanta University